LC
RAPP

Lindbrook Capital’s Rapport Therapeutics RAPP Stock Holding History

Lindbrook Capital’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$150 Buy
+15
New +$195 ﹤0.01% 2727

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Lindbrook Capital's RAPP Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Rapport Therapeutics (RAPP) in Q1 2025: 15 shares worth $150. The stake represents ﹤0.01% of the portfolio and ranks #2727 among its holdings.

77 funds tracked by Wall St. Rank hold RAPP as of Q1 2025.

  • Lindbrook Capital held 15 shares of Rapport Therapeutics worth $150 as of Q1 2025.
  • Rapport Therapeutics was a new Lindbrook Capital position in Q1 2025.
  • Rapport Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2727 holding.
  • 77 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.